Anticorps Recombinant de lapin anti-Phospho-p38 MAPK (Thr180/Tyr182)

Phospho-p38 MAPK (Thr180/Tyr182) Recombinant Antibody for WB, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications(1)

CloneNo.

242308D3

N° de cat : 81212-2-RR

Synonymes

p38 (Thr180/Tyr182), p38 MAPK (Thr180/Tyr182), phospho-p38, phospho-p38 (Thr180/Tyr182), Phospho-p38 MAPK

---

Galerie de données de validation

• 

  WB analysis using 81212-2-RR

  Non-treated NIH/3T3 cells, UV treated and Anisomycin treated NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 81212-2-RR (Phospho-p38 MAPK (Thr180/Tyr182) antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as a loading control.

• 

  WB analysis using 81212-2-RR

  Non-treated HeLa cells and Anisomycin treated HeLa cells were subjected to SDS PAGE followed by western blot with 81212-2-RR (Phospho-p38 MAPK (Thr180/Tyr182) antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as a loading control.

• 

  IHC staining of human colon cancer using 81212-2-RR

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 81212-2-RR (Phospho-p38 MAPK (Thr180/Tyr182) antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: Anisomycin treated HeLa cells, cellules NIH/3T3 traitées à l'anisomycine, cellules NIH/3T3 traitées au UV
• Résultats positifs en IHC: tissu de cancer du côlon humain, ; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:2000-1:10000
• Immunohistochimie (IHC): IHC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 1 publications below

Informations sur le produit

81212-2-RR cible Phospho-p38 MAPK (Thr180/Tyr182) dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: mitogen-activated protein kinase 14
• Masse moléculaire calculée: 360 aa, 41 kDa
• Poids moléculaire observé: 38-42 kDa
• Numéro d’acquisition GenBank: BC031574
• Symbole du gène: p38 MAPK
• Identification du gène (NCBI): 1432
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Protein A purfication
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

A stress-activated serine/threonine protein kinase, p38 mitogen-activated protein kinase (p38 MAPK), belongs to the MAP kinase superfamily. Diverse extracellular stimuli, including ultraviolet light, irradiation, heat shock, high osmotic stress, proinflammatory cytokines and certain mitogens, trigger a stress-regulated protein kinase cascade culminating in activation of p38 MAPK through phosphorylation on a TGY motif within the kinase activation loop. The p38 MAPK undergoes dual phosphorylation at Thr182 and Tyr180 in the Thr-Gly-Tyr activation loop by MAP kinase kinase 6 (MKK6). Upon activation, p38 MAPK phosphorylates multiple substrates, including MAPK activated protein kinase 2 (MAPKAPK2) and activating transcription factor 2 (ATF-2). (PMID: 26901653, PMID: 10807318)

Publications

Species	Application	Title
human	WB	J Med Chem; Discovery of Novel Oxazolo[4,3-f]purine Derivatives as Antitumor Agents through PPIA Interaction; Authors - Xian-Jia Li

{{ptg:RelatedPrimaryAntibodies}}